FLECAINIDE ACETATE
PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA·+4
WEST-WARD,INC.
Indication
Paroxysmal atrial fibrillation
Paroxysmal atrial fibrillation is a supraventricular tachyarrhythmia characterized by sudden, intermittent episodes of rapid, chaotic electrical activation in the cardiac atria that produce an irregularly irregular ventricular rhythm. Read more about Paroxysmal atrial fibrillation
39 drugs 34 manufacturers
Drugs that treat it
Common Paroxysmal atrial fibrillation therapies.
FLECAINIDE ACETATE
PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA·+4
COUNTY LINE PHA
FLECAINIDE ACETATE
PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA·+4
COUNTY LINE PHA
PROPAFENONE HCL
PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA·+4
QUALITEST/PAR P
FLECAINIDE ACETATE
ANTIARRHYTHMIC - CLASS IC·PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA·+4
RISING PHARM
FLECAINIDE ACETATE
ANTIARRHYTHMIC - CLASS IC·PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA·+4
Hikma Pharmaceuticals USA
FLECAINIDE ACETATE
ANTIARRHYTHMIC - CLASS IC·PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA·+4
EPIC PHARMA LLC
FLECAINIDE ACETATE
ANTIARRHYTHMIC - CLASS IC·PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA·+4
AVPAK
FLECAINIDE ACETATE
ANTIARRHYTHMIC - CLASS IC·PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA·+4
A-S MEDICATION
Filter & compare in the drug finder →Opens the drug finder with Paroxysmal atrial fibrillation preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonParoxysmal atrial fibrillation is a supraventricular tachyarrhythmia characterized by sudden, intermittent episodes of rapid, chaotic electrical activation in the cardiac atria that produce an irregularly irregular ventricular rhythm.
Predominantly triggered by rapid focal firing within the pulmonary veins, this subtype is clinically defined by episodes that terminate spontaneously or with intervention within seven days of onset, typically resolving within 24 to 48 hours.
Affecting the cardiovascular system in both structurally normal and diseased hearts, it commonly manifests as palpitations, dyspnea, and fatigue, while presenting an elevated risk of thromboembolism and ischemic stroke due to stasis within the fibrillating atrial appendages.
- nih.gov
Paroxysmal atrial fibrillation is a supraventricular tachyarrhythmia characterized by sudden, intermittent episodes of rapid, chaotic electrical activation in the cardiac atria that produce an irregularly irregular ventricular rhythm Affecting the cardiovascular system in both structurally normal and diseased hearts, it commonly manifests as palpitations, dyspnea, and fatigue, while presenting an elevated risk of thromboembolism and ischemic stroke due to stasis within the fibrillating atrial ap...
- acc.org
Paroxysmal atrial fibrillation is a supraventricular tachyarrhythmia characterized by sudden, intermittent episodes of rapid, chaotic electrical activation in the cardiac atria that produce an irregularly irregular ventricular rhythm Predominantly triggered by rapid focal firing within the pulmonary veins, this subtype is clinically defined by episodes that terminate spontaneously or with intervention within seven days of onset, typically resolving within 24 to 48 hours
- nih.gov
Predominantly triggered by rapid focal firing within the pulmonary veins, this subtype is clinically defined by episodes that terminate spontaneously or with intervention within seven days of onset, typically resolving within 24 to 48 hours
- nih.gov
Predominantly triggered by rapid focal firing within the pulmonary veins, this subtype is clinically defined by episodes that terminate spontaneously or with intervention within seven days of onset, typically resolving within 24 to 48 hours
- nih.gov
Affecting the cardiovascular system in both structurally normal and diseased hearts, it commonly manifests as palpitations, dyspnea, and fatigue, while presenting an elevated risk of thromboembolism and ischemic stroke due to stasis within the fibrillating atrial appendages
- heart.org
Affecting the cardiovascular system in both structurally normal and diseased hearts, it commonly manifests as palpitations, dyspnea, and fatigue, while presenting an elevated risk of thromboembolism and ischemic stroke due to stasis within the fibrillating atrial appendages
Personalize your experience
Follow Paroxysmal atrial fibrillation and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.